Advances in hypertension as reported at ACC 2025 include two new therapies that achieve significant blood pressure (BP) reduction, and a comparison of renal denervation methods for resistant BP.

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...